Fenwick Represents iRhythm in $287.5M Acquisition of VitalConnect

Fenwick is representing iRhythm Holdings, Inc. (Nasdaq: IRTC), a digital health care company focused on creating trusted solutions that detect, predict and prevent disease, in its pending acquisition of Vital Connect, Inc. (“VitalConnect”), a privately held leader in wearable biosensor technology and ambulatory cardiac monitoring.

Upon closing, the transaction is expected to immediately expand iRhythm's addressable market and advance its evolution into a broader cardiac monitoring and intelligence platform. iRhythm intends to acquire VitalConnect for total consideration of approximately $287.5 million. The consideration is expected to consist of approximately $237.5 million in cash and approximately $50 million in iRhythm common stock. More information can be obtained from iRhythm’s announcement.

The Fenwick transaction team includes corporate partners Michael Brown and Ryan Slunaker, associates Brandon Ho and Guy Rotstein and law clerk Morgan Martin; capital markets partner Jennifer Hitchcock and associates Lexi Smith and Warren Pugash; technology transactions partner Stefano Quintini and associates Kehl Sink, Andrew Martinez and Emma Phillips; executive compensation and employee benefits partner Matt Cantor and associates Jonathan Stephenson and Melita Chan; privacy and cybersecurity partner Ana Razamazma, counsel Sari Ratican and associate Kayla Tanaka; antitrust and competition partner Tom Ensign, counsel Meredith Mommers and associate Vaibs Srikaran; patent partner Antonia Sequeira, counsel Brian Hopkins and associates Fredrick Tsang, Matthew Lem and Luke Holbrook; and tax partner William Skinner and associate Justin Folk.